Jean-Laurent Legeay

Jean-Laurent Legeay
Name	Jean-Laurent Legeay
Birth date	1947
Birth place	France
Occupation	Physician, Clinical Researcher, Ethicist
Alma mater	Université Paris Descartes
Known for	Clinical research methodology, Research ethics

Jean-Laurent Legeay is a French physician and clinical researcher noted for his work in clinical pharmacology, clinical trial methodology, and research ethics. He has been active in academic medicine and regulatory discussions in France and Europe, contributing to debates on human subjects protection, informed consent, and the design of therapeutic trials. His career bridges clinical practice, institutional review, and scholarly publication.

Early life and education

Legeay was born in France in 1947 and pursued medical training at Université Paris Descartes, completing medical studies and postgraduate specialization in clinical pharmacology. During his formative years he trained in hospitals associated with Assistance Publique–Hôpitaux de Paris and engaged with research groups connected to Inserm and CNRS. His early exposure included mentorship from clinicians and researchers affiliated with institutions such as Hôpital Necker–Enfants Malades and collaborations involving regulatory contacts at Ministry of Health (France), shaping his orientation toward clinical trials and ethical oversight.

Academic and research career

Legeay held academic appointments and clinical posts that linked university departments and hospital research units, working within frameworks of Université Paris Descartes and affiliated research centers. He participated in multicenter projects involving agencies like Agence nationale de sécurité du médicament et des produits de santé and international collaborations with groups connected to European Medicines Agency and World Health Organization. His roles included oversight of investigator-initiated trials, development of protocol standards, and participation in institutional review processes at university hospitals connected to Hôpital Cochin and regional clinical research networks. Legeay also engaged with professional organizations such as Société Française de Pharmacologie and contributed to training programs linked to Fondation pour la Recherche Médicale.

Contributions to medical ethics and clinical research

Legeay’s contributions intersected with debates involving Declaration of Helsinki, Good Clinical Practice standards, and national regulations administered by Agence régionale de santé structures. He emphasized participant protection in clinical trials, advocating rigorous consent processes and transparent risk-benefit assessment in conjunction with ethics committees like Comité de Protection des Personnes and institutional review boards influenced by frameworks from Council of Europe instruments. Legeay addressed tensions between academic independence and pharmaceutical sponsorship represented by entities such as European Federation of Pharmaceutical Industries and Associations in public discussions, promoting methodological integrity in trials modeled on approaches from Randomized controlled trial designs and adaptive trial methodology seen in modern oncology studies linked to Institut Gustave Roussy.

His ethical writing engaged with topics including vulnerable populations in research observed in studies from World Medical Association contexts, data monitoring influenced by practices at Data and Safety Monitoring Board forums, and post-trial access discussions resonant with guidelines from Council for International Organizations of Medical Sciences. Legeay also contributed to policy advisories that intersected with regulatory jurisprudence from bodies such as Conseil d'État and parliamentary health committees in France.

Publications and notable works

Legeay authored and coauthored articles and chapters on clinical pharmacology, trial conduct, and research ethics, publishing in outlets that include journals tied to institutions like Revue Médicale Interne and specialty periodicals affiliated with Inserm and Société Française d'Anesthésie et de Réanimation. His writings addressed trial design, adverse event reporting standards comparable to initiatives by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and ethical frameworks reflecting principles from Declaration of Helsinki revisions. He contributed to consensus statements and guideline documents alongside experts from Haute Autorité de Santé and participated in edited volumes produced with collaborators affiliated with Université Paris Descartes and European university presses. Notable works discuss informed consent models, risk communication consistent with research from European Society for Clinical Pharmacology and Therapeutics, and procedural safeguards for pediatric research linked to practices at Hôpital Necker–Enfants Malades.

Awards and recognitions

Throughout his career Legeay received professional recognition from French and European professional bodies, earning distinctions and invitations to speak at congresses organized by Société Française de Pharmacologie and international meetings held under umbrellas such as European Society of Clinical Pharmacology and Therapeutics and World Health Organization symposia. He was acknowledged by academic departments at Université Paris Descartes and received honors from institutional partners including hospital research centers tied to Assistance Publique–Hôpitaux de Paris for contributions to clinical research quality and ethics. His work informed institutional policies and was cited in reports by regulatory organizations such as Agence nationale de sécurité du médicament et des produits de santé.

Personal life and legacy

Legeay’s personal life remained centered in France, with professional ties to Parisian hospitals and universities. His legacy endures through trainees and collaborators in clinical pharmacology and research ethics who continued work at institutions like Inserm, Université Paris Descartes, and clinical sites within Assistance Publique–Hôpitaux de Paris. His influence is visible in protocol standards, ethics committee practices, and educational curricula in French medical faculties and in the broader European discussion on responsible clinical research. He is remembered by peers associated with organizations such as Société Française de Pharmacologie and by regulatory colleagues at Haute Autorité de Santé for his measured advocacy of participant protection and methodological rigor.

Category:French physicians Category:Clinical pharmacologists Category:Medical ethicists